CEO Executive AssistantHearing and Audiology Program Coordination Requires Administrative Precision Across Clinical, Regulatory, and Market Dimensions
Hearing and audiology program coordination has gained strategic prominence for healthcare CEOs as the clinical, regulatory, and market dimensions of hearing health have all shifted simultaneously. The Joint Commission on Infant Hearing has established newborn hearing screening standards that carry compliance obligations across health systems with labor and delivery programs. The FDA’s authorization of over-the-counter hearing aids has created a competitive dynamic that directly affects how health systems position their hearing aid program economics. Cochlear implant programs require multidisciplinary coordination between audiology, otolaryngology, and neurology in ways that demand consistent executive governance. And the integration of audiology with ENT and neurology service lines is increasingly a strategic question with material revenue and patient experience implications.
For healthcare CEOs, managing this complexity means maintaining governance visibility across a service line that spans clinical quality, regulatory compliance, retail market competition, and specialist integration. The administrative architecture that makes that governance possible is the executive assistant’s domain.
This article explains how skilled EAs support healthcare CEOs on hearing and audiology program coordination: scheduling service line leadership reviews, managing OTC market strategy briefings, tracking JCIH compliance reporting, coordinating cochlear implant program reviews, and preparing board presentations that give directors the governance visibility they require.
Scheduling Audiology Service Line Leadership Reviews
Audiology as a service line sits in an unusual position within most health system organizational structures. It may report through ENT and otolaryngology, through rehabilitation services, through primary care, or through a standalone ambulatory care division, depending on the organization’s history and structure. Wherever it sits organizationally, the service line needs a clear governance rhythm that connects its clinical, operational, and financial performance to CEO-level accountability.
The EA establishes a quarterly audiology service line leadership review that convenes the CEO, the Chief Medical Officer or service line medical director, the VP of Operations for the relevant division, the audiology program director, the finance partner for the service line, and the head of hearing aid retail operations if the organization runs a hearing aid dispensing program. These sessions review clinical quality metrics, patient access and volume trends, operational performance, financial results, and the forward strategic agenda for the service line.
Building this review series requires the EA to work with the service line leadership team at the start of each year to understand the audiology program’s current performance status, the most significant challenges it faces, and the governance questions that genuinely require CEO attention versus those that can be resolved at the service line level. The quarterly review agenda should reflect that calibration: the CEO’s time is most valuable when directed at decisions and strategic questions, not at status reporting that could be summarized in a two-page document.
Pre-read materials for audiology service line reviews should be submitted 72 hours in advance and structured to cover clinical quality metrics including hearing test volume and outcomes, patient satisfaction scores, any adverse event or quality concern summaries, financial performance against plan, operational capacity and access metrics, and the status of any strategic initiatives the CEO has previously directed. The EA reviews submissions for completeness and ensures the agenda reflects a clean decision structure rather than an undifferentiated status summary.
Between quarterly reviews, the EA schedules monthly working touchpoints between the CEO and the service line medical director for informal alignment. These touchpoints keep the CEO current on emerging clinical or operational issues without requiring a full governance convening every month and create a channel for the medical director to raise concerns that cannot wait for the quarterly review cycle.
Coordinating Hearing Aid Program and OTC Market Strategy Briefings
The FDA’s authorization of over-the-counter hearing aids, effective October 2022, fundamentally changed the competitive landscape for health system hearing aid programs. Consumers with mild to moderate hearing loss can now purchase hearing aids without a provider visit, audiologist fitting, or prescription from major consumer electronics and pharmacy retailers at price points significantly below traditional audiologist-dispensed devices. For healthcare CEOs, the OTC market shift requires a strategic response: whether to compete more aggressively on clinical value, whether to partner with OTC device manufacturers, how to position the organization’s hearing aid program in a market that has structurally changed.
The EA coordinates a semi-annual OTC market strategy briefing that brings together the CEO, the Chief Strategy Officer, the audiology program director, and the marketing and consumer strategy teams. The purpose of these briefings is not to review current operational performance: that is the service line review’s role. The purpose is to assess how the OTC market is evolving, how it is affecting the organization’s hearing aid program volume and economics, and what strategic adjustments are warranted.
A well-structured OTC strategy briefing covers four topics: market share data on the OTC hearing aid segment and the trends in consumer adoption by age and hearing loss severity, the performance of the organization’s hearing aid dispensing program relative to the prior year and relative to the original volume projections made before OTC authorization, competitive intelligence on how other health systems and audiology-focused companies are responding to OTC market pressure, and strategic options for the organization with a clear recommendation from the strategy team for CEO consideration.
The EA works with the strategy team to establish this agenda structure and requires a briefing memo submitted one week before each OTC strategy session. The CEO should enter these sessions having read a substantive brief rather than receiving market orientation during the meeting itself. The meeting’s value is in the strategic dialogue that the brief makes possible.
When a specific OTC market development requires CEO attention between the semi-annual briefing cycle, the EA manages the scheduling of an ad hoc session with appropriate preparation time. Developments that warrant expedited briefing include a significant competitor announcing a new OTC partnership program, a material quarter-over-quarter shift in the organization’s hearing aid program volume that appears OTC-related, or a regulatory development affecting OTC device standards.
Tracking JCIH Newborn Hearing Screening Compliance Reporting
The Joint Committee on Infant Hearing (JCIH) establishes evidence-based standards for the Early Hearing Detection and Intervention (EHDI) program, which requires that all newborns be screened for hearing loss before discharge, that those who do not pass screening receive audiologic evaluation by three months, and that those confirmed to have hearing loss receive early intervention services by six months. These timelines, often described as the 1-3-6 benchmarks, are tracked and reported by state EHDI programs and are subject to oversight by state health departments and CMS.
For healthcare CEOs at health systems with significant birth volume, JCIH compliance is both a clinical quality obligation and a regulatory accountability. Failure to meet EHDI benchmarks can generate state health department scrutiny, affect Medicaid and CHIP billing relationships, and damage community trust in the organization’s commitment to maternal and newborn care quality.
The EA builds and maintains the JCIH compliance reporting calendar, which maps state EHDI reporting deadlines, internal compliance review meetings, and any state health department audit or monitoring visits. This calendar is integrated into the CEO’s governance view alongside other regulatory reporting obligations so that EHDI deadlines are never treated as peripheral.
The EA schedules a quarterly JCIH compliance review that convenes the CEO, the Chief Quality Officer, the labor and delivery VP, the audiology program director, and the EHDI coordinator. The agenda covers the organization’s current performance on the 1-3-6 benchmarks, any barriers to achieving the benchmarks for specific patient populations, the status of any improvement initiatives the CEO has previously directed, and any upcoming state reporting obligations. A quarterly cadence is sufficient for stable programs; if performance on any benchmark drops below the state average, the EA escalates to a monthly review cadence until the gap is addressed.
State EHDI reporting submissions that require CEO attestation or signature are tracked by the EA with a preparation timeline that begins six weeks before the submission deadline. The EA confirms with the compliance team when the data will be finalized, schedules the CEO review session, and ensures any attestation documentation is executed and filed on time. Late or incomplete EHDI submissions create regulatory exposure that is entirely preventable with proper advance tracking.
Healthcare CEO patient advocacy coordination provides related context on how EAs support CEOs managing programs where early identification and community outreach are critical to meeting clinical and compliance benchmarks.
Managing Cochlear Implant Program Review Meetings
Cochlear implant programs are among the most clinically and operationally complex subspecialty services a health system operates. They require a multidisciplinary team including audiologists, otolaryngologists, speech-language pathologists, and in some programs neurologists and geneticists. They involve expensive devices, highly technical surgical procedures, and a post-implant rehabilitation process that can extend over years. For many patients, cochlear implantation is a life-changing intervention; for the health system, it is a high-cost, high-reputational-stakes program that requires consistent executive governance.
The EA establishes an annual cochlear implant program review that brings together the CEO, the Chief Medical Officer, the surgical program director, the audiology program director, and the finance team. The review should cover program volume and case mix, clinical outcomes relative to national benchmarks, device and implant cost management, insurance authorization and reimbursement trends, and the program’s strategic position relative to competitors in the region.
Annual reviews are appropriate for a program whose clinical protocols and volume tend to be relatively stable year over year. However, when a significant program development warrants CEO attention, the EA schedules an ad hoc review outside the annual cycle. Developments that warrant expedited attention include a change in payer coverage policy for cochlear implantation affecting a significant portion of the patient population, a new competitor entering the regional market, a significant clinical outcome concern requiring quality review, or a capital request for new equipment or program expansion.
Cochlear implant program reviews require briefing materials that are more clinically detailed than typical service line reviews, because the quality and safety dimensions of cochlear implant care are central to the governance conversation. The EA works with the medical director and quality team to ensure the CEO review preparation includes a clear summary of clinical outcome data in terms the CEO can engage with meaningfully, not raw clinical metrics that require specialist translation at the table.
For programs seeking to expand cochlear implant services, the EA manages the strategic planning process that precedes the capital request: scheduling the market analysis review with strategy, the clinical program design review with medical leadership, and the financial modeling review with finance, in a sequence that ensures each subsequent meeting builds on the prior one’s conclusions. This sequential discipline prevents the capital request from arriving before the strategic and clinical case has been fully built.
Preparing Board Presentations on Audiology Program Volume, Hearing Aid Retail Strategy, and Service Line Integration
Board presentations on hearing and audiology program coordination span three distinct but related domains: audiology program clinical and financial performance, hearing aid retail program strategy in the context of the OTC market shift, and the integration of audiology with ENT and neurology service lines. Directors who are engaged in service line governance will have informed views on all three; the CEO’s presentation should give them the analytical depth to engage productively.
The EA manages the board presentation preparation timeline with a three-week structure beginning at the start of each board cycle where hearing and audiology is on the agenda. The first step is confirming with the CEO and the service line leadership what the board presentation needs to accomplish: is this a routine performance update, a strategic discussion about the OTC market response, a capital request for program expansion, or a review of integration progress with ENT or neurology? The objective determines the content structure, the contributors, and the level of analytical rigor required.
For presentations covering OTC market strategy, the EA ensures the strategy team’s analysis is incorporated with clear benchmarking against peer health systems that have made visible strategic moves in response to OTC market pressure. Directors who follow healthcare strategy will know that other health systems are making decisions about hearing aid program economics in the OTC era, and the CEO should present the organization’s strategic position with an informed view of what peers are doing and why the chosen strategy is differentiated.
Service line integration presentations require particular attention to the clinical and operational rationale for integration with ENT and neurology. The most effective arguments for integration are grounded in patient pathway data: how many audiology patients have concurrent ENT or neurology conditions that require coordinated care, how much does lack of integration cost in patient experience and care quality, and what does the integration investment purchase in terms of clinical outcome improvement? The EA works with the data analytics and clinical integration teams to ensure this patient pathway analysis is incorporated before the board presentation is finalized.
According to McKinsey’s research on healthcare service line strategy, health systems that achieve sustained service line performance improvements consistently demonstrate structured executive engagement: regular governance reviews, disciplined performance tracking, and rigorous board reporting that connects operational metrics to strategic objectives. The administrative infrastructure the EA maintains is a direct contributor to those outcomes.
Healthcare CEO physician enterprise coordination covers how EAs structure the ENT and neurology physician relationship governance that underpins successful audiology service line integration.
Administrative Excellence as the Foundation of Audiology Program Governance
Hearing and audiology program coordination is a governance domain where administrative precision has direct clinical implications. The JCIH compliance reporting cycle that slips affects newborns who needed timely hearing loss identification. The cochlear implant program review that lacks clinical outcome data produces a board conversation that cannot assess program quality. The OTC strategy briefing that arrives without competitive analysis leaves the CEO making strategic decisions with incomplete information.
The EA who builds and maintains the scheduling architecture, tracks the EHDI reporting deadline, ensures the cochlear implant review includes real clinical outcome data, and prepares the board presentation with the analytical rigor that directors require is not performing support work that runs alongside the CEO’s clinical governance. They are one of the conditions on which that governance is possible.
Hearing and audiology program coordination demands exactly that standard of administrative support. EAs who deliver it give their CEOs a structural advantage in a service line that combines clinical complexity, regulatory accountability, and market dynamics in ways that reward disciplined executive governance.